BioNTech to Shutter Germany, Singapore Sites After Failed Sale
BNTX sits 22% above its 52-week low of $79.52.
Summary
BioNTech will close manufacturing sites in Germany and Singapore after failing to find buyers, affecting up to 1,860 jobs. The company had announced in May it would seek buyers or wind down these sites as part of transferring COVID-19 vaccine production to Pfizer. This follows a series of setbacks including a terminated Phase 2 trial, slashed revenue guidance, and co-founder departures. The closures signal a definitive exit from pandemic-era manufacturing and further restructuring costs, though the company has agreed on redundancy terms with the works council. Watch for details on restructuring charges and any impact on the $1B buyback program.
At the time of this announcement, BNTX was trading at $97.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.7B. The 52-week trading range was $79.52 to $124.00. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.